This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== Pathway == The ANGPTL8 regulatory pathway has been constructed recently by integrating the information of its known transcription factors which is available at WikiPathways data repository with the pathway id WP3915.
=== Moondust: Knuckles Tech Demos === Moondust: Knuckles Tech Demos is a tech demo created for the Valve Index controllers which is set in the Portal universe. The game was released on Steam on June 21, 2018, however it is unlisted.
== Scientific evaluation == The German Institute for International and Security Affairs (SWP) recognized a rise in the Shiite Badr organization since 2014 under the leadership of its Secretary General Hadi al-Amiri. In 2017, SWP wrote that the Badr organization is one of "the most important actors in Iraqi politics". It has become the most important instrument of Iranian politics in Iraq. Its aim is "to exert the greatest possible influence on the central government in Baghdad and at the same time to build the strongest possible Shiite militias that are dependent on Iran". The foundation compared the role of the organization with that of Hezbollah in Lebanon.
In 1801, the civil parishes that form the modern borough had a total population of 2,022. This rose slowly throughout the nineteenth century, as the district became built up; reaching 5,646 in the middle of the century. When the railways arrived the rate of population growth increased. The population took five decades to rebound to the more muted peak of the 1950s, when much industry relocated from London, further boosting the speed of the wave of new housing then built. Brent is the most diverse locality in the UK by country of birth. It in 2019 became the only local authority with over 50% of residents, namely 52%, born abroad. Large Asian and Indian, Black African, Black Caribbean, Irish, and Eastern European communities exist. 45 per cent of the population was a minority ethnicity in the 1991 census, the most in England at the time. In 1991 17.2% were Indian, 10.2% were Black Caribbean and 9% were Irish. Brent was the only Outer London borough combining high proportions of Indian and Afro-Caribbean ethnicities. The 2001 UK Census found that the borough had a population of 263,464 residents, of whom 127,806 were male, and 135,658 female. Of those stating a choice, 47.71% described themselves as Christian, 17.71% as Hindus, 12.26% as Muslims and 10% as having no religion. Among residents, 39.96% were in full-time employment and 7.86% in part-time employment – compared to a London average of 42.64% and 8.62%, respectively.
Industrial Union Department v. American Petroleum Institute Six-membered aromatic rings with one carbon replaced by another element: borabenzene, silabenzene, germabenzene, stannabenzene, pyridine, phosphorine, arsabenzene, stibabenzene, bismabenzene, pyrylium, thiopyrylium, selenopyrylium, telluropyrylium
Sources: en.wikipedia.org
== Medical uses == The spectrum of action includes many Gram-positive and Gram-negative bacteria (including Pseudomonas) and anaerobic bacteria. The overall spectrum is similar to that of imipenem, although meropenem is more active against Enterobacteriaceae and less active against Gram-positive bacteria. Meropenem is effective against bacteria producing extended-spectrum β-lactamases but may be more susceptible to hydrolysis by metallo-β-lactamases produced by bacteria. β-lactamases are enzymes that bacteria produce to hydrolyze β-lactam antibiotics, breaking the β-lactam ring and rendering these antibiotics ineffective. This mechanism helps bacteria resist the effects of antibiotics like penicillins, cephalosporins, and carbapenems, making treatment more challenging. While β-lactam ring in meropenem is more accessible to water molecules than in the other β-lactam antibiotics, that facilitates the hydrolysis process and faster degradation of meropenem's antibacterial properties in aqueous solutions, it is more resistant to degradation by β-lactamase enzymes produced by bacteria than the other β-lactam antibiotics. Meropenem is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with hematological malignancies and cancer patients receiving anticancer drugs that suppress bone marrow formation. Meropenem is approved for complicated skin and skin structure infections, complicated intra-abdominal infections and bacterial meningitis. Meropenem is effective in treating bacterial pneumonia, including hospital-acquired pneumonia.
== Biochemistry at Yale == In 1945, after Max Bergmann's death, Fruton joined the Yale University Department of Physiological Chemistry (part of the medical school) —headed then by C. N. Hugh Long—where he taught biological chemistry to medical students. Fruton joined a growing science faculty, which included the editor of the Journal of Biological Chemistry, Rudolph Anderson; biochemist Edward Tatum also came to Yale at the same time. In addition to research and teaching at Yale, in 1948 Fruton visited the laboratories of several eminent biochemists: Kaj Linderstrøm-Lang's chemistry department at the Carlsberg Laboratory; Hugo Theorell's lab in Stockholm; and Alexander Todd's lab at Cambridge University. At the end of his five-year appointment as assistant professor, Fruton was promoted to full professor received a joint appointment in the chemistry department—at the time, the only Jewish full professor in the medical school. By 1952, he was elected to the National Academy of Sciences, and that year he also became chairman of the Department of Physiological Chemistry (which was renamed Biochemistry, reflecting the shift in research focus from medical to general biological problems). He was elected to the American Academy of Arts and Sciences in 1953. Most of Fruton's early research at Yale was funded by a grant from the Rockefeller Foundation; Warren Weaver was making enzymology one of the Foundation's research focuses. Fruton headed a growing lab that included doctoral students, postdoctoral researchers, and technical assistants.
Degenerative disc disease (DDD) is a medical condition typically brought on by the aging process in which there are anatomic changes to and/or loss of function of one or more intervertebral discs of the spine. DDD can take place with or without symptoms, but is typically identified once symptoms arise. The root cause is thought to be loss of soluble proteins within the fluid contained in the disc, with resultant reduction of the oncotic pressure, which in turn causes loss of fluid volume. Normal downward forces cause the affected disc to lose height, and the distance between vertebrae is reduced. The anulus fibrosus, the tough outer layer of a disc, also weakens. This loss of height causes laxity of the longitudinal ligaments, which may allow anterior, posterior, or lateral shifting of the vertebral bodies, causing facet joint malalignment and arthritis; scoliosis; cervical hyperlordosis; thoracic hyperkyphosis; lumbar hyperlordosis; narrowing of the space available for the spinal tract within the vertebra (spinal stenosis); or narrowing of the space through which a spinal nerve exits (vertebral foramen stenosis), with resultant inflammation and impingement of a spinal nerve, causing a radiculopathy. DDD can cause mild to severe pain, either acute or chronic, near the involved disc, as well as neuropathic pain if an adjacent spinal nerve root is involved. Diagnosis is suspected when typical symptoms and physical findings are present and confirmed by X-rays of the vertebral column.
=== Primary dentin === Primary dentin, the most prominent dentin in the tooth, lies between the enamel and the pulp chamber (near dentinoenamel junction). The outer layer closest to enamel is known as mantle dentin. This layer is unique to the rest of primary dentin. Mantle dentin is formed by newly differentiated odontoblasts and forms a layer consistently 15-20 micrometers (μm) wide. Unlike primary dentin, mantle dentin lacks phosphorylation, has loosely packed collagen fibrils and is less mineralized. Below it lies the circumpulpal dentin, more mineralized dentin which makes up most of the dentin layer and is secreted after the mantle dentin by the odontoblasts. Circumpulpal dentin is formed before the root formation is completed. Newly secreted dentin is unmineralized and is called predentin. It is easily identified in hematoxylin and eosin stained sections since it stains less intensely than dentin. It is usually 10-47μm and lines the innermost region of the dentin. It is unmineralized and consists of collagen, glycoproteins, and proteoglycans. It is similar to osteoid in bone and is thickest when dentinogenesis is occurring.
Sources: en.wikipedia.org
=== Differential diagnosis === Given the variety and nonspecific nature of symptoms that can be associated with autoimmune diseases, differential diagnosis—determining which of several diseases with similar symptoms is causing a patient's illness—is an important part of the diagnostic process. This often involves ruling out other potential causes of symptoms, such as infections, malignancies, or genetic disorders.
Cancellous bone, spongy bone, or trabecular bone is the internal tissue of the skeletal bone and is an open-cell porous network that follows the material properties of biofoams. Cancellous bone has a higher surface-area-to-volume ratio than cortical bone and it is less dense. This makes it weaker and more flexible. The greater surface area also makes it suitable for metabolic activities such as the exchange of calcium ions. Cancellous bone is typically found at the ends of long bones, near joints, and in the interior of vertebrae. Cancellous bone is highly vascular and often contains red bone marrow where hematopoiesis, the production of blood cells, occurs. The primary anatomical and functional unit of cancellous bone is the trabecula. The trabeculae are aligned towards the mechanical load distribution that a bone experiences within long bones such as the femur. As far as short bones are concerned, trabecular alignment has been studied in the vertebral pedicle. Thin formations of osteoblasts covered in endosteum create an irregular network of spaces, known as trabeculae. Within these spaces are bone marrow and hematopoietic stem cells that give rise to platelets, red blood cells and white blood cells. Trabecular marrow is composed of a network of rod- and plate-like elements that make the overall organ lighter and allow room for blood vessels and marrow. Trabecular bone accounts for the remaining 20% of total bone mass but has nearly ten times the surface area of compact bone.
253No In 1971, Bemis et al. was able to determine an isomeric level decaying with a half-life of 31 s from the decay of 257Rf. This was confirmed in 2003 at the GSI by also studying the decay of 257Rf. Further support in the same year from the FLNR appeared with a slightly higher half-life of 43.5 s, decaying by M2 gamma emission to the ground state.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.